BioCardia, Inc. (BCDA) — Quarterly Report

Key Insights

• BioCardia is classified as a smaller reporting company and non-accelerated filer, indicating limited scale and resources compared to larger peers, which may impact operational efficiency and market competitiveness.
• The company maintains an active ATM (At-The-Market) offering program as of May 13, 2026, suggesting ongoing capital needs and potential dilution risk for existing shareholders as they access equity markets for funding.
• The filing shows detailed tracking of equity components (common stock, additional paid-in capital, retained earnings) with multiple measurement periods, indicating active equity management and potential warrant/option dilution considerations.